initi outperform pt
price wrong
ep notabl posit share lh thesi
cro trend would trend veli increas lab activ
strong underli core would aid multipl except lh
end moder size cro asset chiltern vs
sizabl deal like prxl ppdi major surpris
one pama struggl logic end
ultim price approach cut stay
model adjust realiti multi-year profit reset
said see hit manag particularli given numer
posit factor busi also given likelihood acceler
momentum build cvd w/ recent chiltern deal highli strateg
term factor would point strong book
momentum cvd off-set continu launchpad save
chiltern synergi captur strong underli volum also see
reason ep upsid valuat support tax reform
help sustain ep momentum lieu deeper pama
relat cut set thu discount market in-lin
w/ histor norm see appeal entri point share
potenti upsid risk also potenti relief pama
addit would point multi-year transform lh
current undergo diversifi life scienc provid
ultim bia rel multipl higher given dynam
see risk reward favor thu initi share o/p rate
thing watch revisit pama cvd book
debat big headwind pama prove
chiltern address cvd limitations/help growth investor
reward move divers lh m-lt outlook omx
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk potenti pama relat price cut
bleed commerci price ultim lead neg margin
cycl recent vertic integr hc servic organ lead
increas price pressur given heighten focu unit cost
challeng associ integr small outreach lab deal
could depress return invest capit prove distract
effort off-set pama cut increas cost save could yield
servic challeng ultim depress core organ volum
poor perform major clinic trial could harm cvd reput
lead signific shift cro relat market share
signific down-tick biotech relat fund could lead materi
growth downshift earli phase demand harm profit
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
laboratori corp america hold
initi outperform pt
price wrong
last page report import disclosur regard stock report
tabl content
debat big headwind pama prove
debat chiltern address cvd limitations/help growth
debat m-lt outlook omx
point differenti vs st
iv valuat risk tax reform vs price risk
 conclus initi outperform thesi
lh perform larg track
lead life scienc compani one largest
independ clinic laboratori provid drug
develop servic biopharma client
chiltern lab tuck-in deal help off-set
pama hit valuat still reason
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk pama relat price haircut roll
commerci creat virtuou circl margin pressur
revenu split clinic lab/cro
manag team year industri experi
previous head lh diagnost hospit
health system group
spent year quintil cfo
debat big headwind pama prove
outcom surpris given mani lab includ
pama result sizeabl hw lh
pama controversi start cmss desir
cmss decis estim lh total revenu
conduct market-bas survey lab price
hit bp
lab servic one area
govern pay above-market price
waffl whether includ hospit outreach
lab market much higher rate
septemb announc hospit lab
would includ rate calcul
mean lh repres disproportion
calcul result overal much lower
pama rollback possibl uptick like
price cut probabl realiz
somewhat unusu issu multi-year price
possibl agenc revisit pama
provid relief futur year
dgx/lh independ lab
market mani smaller competitor higher
cost structur therefor like
hurt pama
smaller lab alreadi
bar pama repriev like see small
lab sale correspond decreas price paid
pama unpleas dgx/lh manag potenti disastr small lab
revenu impact total drop downtax affect hit januari
award premium consistency/dividend
lh trade discount
dgx improv perform current manag
dividend piqu investor interest also caus
stock screen posit lot quant fund
comparison lh screen well
hamper earli perform bumpi
respect covanc central lab roll pre deal
lh manag sinc done lot work
turn asset around see question
midst becom broad-bas life
ultim lh strategi work
differ reason appeal differ base
strategi matur acceler growth multipl
multipl begin trend upward mt
ceo comment acquisit
integr part strateg growth expect lh
remain highli acquisit transform
given bn /year convers
compani like continu
acquir tuck-in lab larger cro asset
also model mm repo
ultim strategi gener revenu growth
per year hsd ep growth would bia
multipl higher strategi gain momentum
plenti exampl strong gener entiti
perform improv consist believ investor reward lh
debat chiltern address cvd limitations/help growth
chiltern bring small biopharma client
chiltern strong key oncolog vertic
chiltern bolster geograph presenc apac region
pf organ better suit realiz promis integr lab/cro
debat m-lt outlook omx
launchpad success expect upsiz
expand launchpad covanc busi
continu expans constant improvement/combat
pama see omx w/ mix determin magnitud
robust permit cap alloc boost core
impact lab margin besid pama
mix shift toward higher complex test
posit time
acq depress asset via tuck
long-term margin accret though st
mix impact covanc margin
chiltern lower margin given larger
busi lower margin substanti
increas trial complex also depress
om weigh mix/pama total profit growth remain strong
model summari point differenti vs street
swing factor pama repriev cvd omx trajectori pace outreach
point differenti
larg in-lin
conserv view
launchpad cvd
step-up help partial
ep slightli st
in-lin
reform
respect financi perform spite pama w/ tax reform net
million except per share data fy end septemb volum organ gp growth revenu margin ep share net incom price-to-earnings premium/discount januari
metric remark consist despit underli improv shift toward high growth vertic
risk point favor risk reward profil heighten price pressur vs pama repriev tax reform
potenti pama relat price cut bleed commerci price ultim lead neg margin cycl
recent vertic integr hc servic organ lead increas price pressur given heighten focu unit cost
challeng associ integr small outreach lab deal could depress return invest capit prove distract
effort off-set pama cut increas cost save could yield servic challeng ultim depress core organ volum
poor perform major clinic trial could harm cvd reput lead signific shift cro relat market share
signific downtick biotech relat fund could lead materi growth downshift earli phase demand harm profit
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate assum vs pre tax reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per lh perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
attract asset despit nt pama headwind core growth improv reform support multipl
notabl posit share lh thesi cro trend would trend
veli increas lab activ strong underli core would aid multipl
except lh end moder size cro asset chiltern vs
sizeabl deal like prxl ppdi major surpris one pama
struggl logic end ultim price approach
cut stay model adjust realiti multi-year profit reset
said see hit manag particularli given numer posit factor
busi also given likelihood acceler manag outreach thesi
term factor would point strong book momentum cvd
off-set continu launchpad save chiltern synergi captur strong underli volum
also see reason ep upsid valuat support tax reform help
sustain ep momentum lieu deeper pama relat cut set
thu discount market in-lin w/ histor norm see appeal entri point
share potenti upsid risk also potenti relief pama
addit would point multi-year transform lh current undergo
diversifi life scienc provid ultim bia rel multipl higher
given dynam see risk reward favor thu initi share o/p rate
thing watch revisit pama cvd book momentum omx trajectori
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti pama relat price cut bleed commerci price ultim lead neg
margin cycl recent vertic integr hc servic organ lead increas price pressur given heighten focu
unit cost challeng associ integr small outreach lab deal could depress return invest capit prove
distract effort off-set pama cut increas cost save could yield servic challeng ultim depress core
organ volum poor perform major clinic trial could harm cvd reput lead signific shift cro
relat market share signific down-tick biotech relat fund could lead materi growth downshift earli phase
articl articl
time dissemin januari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
